Full-Line Integrated Continuous Process from Upstream to Downstream
24th September 2019 | 09:00am BST/ 10:00am CEST/ 16:00PM China Time | Jackal Tsou, Team Supervisor of Downstream Process Development and Gerben Zijlstra, Global Technology Consultant at Sartorius Stedim Biotech |BOOK FREE SEAT
As the development process of monoclonal antibodies has come to a steady, it is assumed the automatic flow can be adopted and it is the beginning test ground for continuous manufacturing, to link the upstream cultivation to downstream purification in a continuous mode. We will show some preliminary results for this new era, Biomanufacturing 4.0.
Presented by Jackal Tsou, Team Supervisor of Downstream Process Development at Mycenax Biotech Inc.
And Gerben Zijlstra, Global Technology Consultant at Sartorius Stedim Biotech
Gerben is a regular speaker on process intensification, process integration and continuous biomanufacturing. He received his Ph.D. from the University of Wageningen (The Netherlands) in the field of process integration in animal cell culture.
He has worked for more than 20 years at CMO DSM Biologics and has been involved in the development of several commercial Bio-therapeutics, as well as innovation projects. He was one of the early adopters of single-use bioreactors and is the first inventor of the Concentrated Fed-Batch – XD® technology, amongst others licensed by Amgen. Gerben was deeply involved in the scale-up and tech transfer of XD® technology to the Brisbane (Australia) site, which later received the 2014 ISPE facility of the year award for process innovations.
Subsequently, as a consultant at Xendo, Gerben has been working on several Continuous BioManufacturing as well as Gene Therapy projects. Since end of 2016 he has joined the Sartorius Stedim Biotech Marketing Team, where he currently holds a position as Global Tech Expert for Intensified and Continuous BioManufacturing.
Sponsored by Sartorius Stedim Biotech
Sartorius Stedim Biotech is a leading international supplier of products and services that enable the biopharmaceutical industry to develop and manufacture drugs safely and efficiently. As a total solutions provider, Sartorius Stedim Biotech offers a portfolio covering nearly all steps of biopharmaceutical manufacture. The company focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Headquartered in Aubagne, France, Sartorius Stedim Biotech is quoted on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. In 2016, the company employed approx. 4,700 people, and earned sales revenue of 1,052 million euros.